Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, rubella and varicella vaccine (live)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The measles-mumps-rubella-varicella (MMRV) vaccine is a live attenuated combination biologic used for the active immunization of children against four viral diseases: measles, mumps, rubella, and varicella (chickenpox). By combining these antigens into a single injection, the vaccine simplifies pediatric immunization schedules and improves compliance. Commercially available versions include Merck's ProQuad and GSK's Priorix-Tetra. The vaccine works by inducing a humoral and cellular immune response against the respective viruses, providing long-term protection. In clinical studies, it is often evaluated for safety and immunogenicity when co-administered with other routine pediatric vaccines like meningococcal conjugate vaccines (e.g., Menactra).
- Brand names
- ProQuadPriorix-Tetra
- Other names
- MMRVMMRV vaccinemeasles-mumps-rubella-varicella vaccine
02
Targets
PRR (Pattern recognition receptors)CADM1 (Cell adhesion molecule 1)Measles virus entry receptorsSia (Alpha-2,3-linked sialic acid receptor)
Beyond the preview
Go deeper on measles, mumps, rubella and varicella vaccine (live).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, rubella and varicella vaccine (live).